Newsfeeds - Spark Newswire

1 minute read

FDA
News

Minerva Neurosciences Confirms FDA’s Refuse Letter From Oct. 14, 2022 Remains In Effect

Today, 6:50 AM

Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that, following the Type

NERV

2 minute read

Movers

12 Health Care Stocks Moving In Tuesday’s After-Market Session

By Benzinga Insights

Today, 6:50 AM

Gainers

ARAV

1 minute read

Legal
News

Minerva Neuroscience Granted Australian Patent Titled ‘Use of phenoxypropylamine compounds to treat depression’

By Benzinga Newsdesk

Today, 6:50 AM

http://pericles.ipaustralia.gov.au/ols/auspat/applicationDetails.do?applicationNo=2020205268#

NERV

2 minute read

Why IBM Shares Are Trading Higher; Here Are 21 Stocks Moving Premarket

By Lisa Levin

Today, 6:50 AM

Gainers COMSovereign Holding Corp. (NASDAQ: COMS) rose 20.9% to $0.1063 in pre-market trading after dipping 26% on Wednesday. COMSovereign recently announced receipt of Nasdaq listing determination.

6 minute read

Why Minerva Neurosciences Shares Dipped By Around 70%; Here Are 90 Biggest Movers From Yesterday

By Lisa Levin

Today, 6:50 AM

Gainers Acorda Therapeutics, Inc. (NASDAQ: ACOR) surged 163.8% to close at $0.8970 on Monday after the company announced a $16.5 million award and royalty/supply relief in the AMPYRA arbitration case.

ACOR